Splash Beverage Group Expands CannEpil® License to Veterinary Use

What Happened
Splash Beverage Group, Inc. (SBEV) announced on July 29, 2026 (via Form 8-K) that it entered into an addendum to its exclusive global license agreement with Argent BioPharma Limited for CannEpil®. The addendum expands the licensed field to include veterinary applications, revises royalty rates for human and veterinary sales, and extends certain deadlines under the original July 6, 2026 license agreement. A press release about the expansion was also furnished with the 8-K.

Key Details

• The addendum was filed July 29, 2026 and amends the original License Agreement dated July 6, 2026.
• Royalty rates were set at 10% of Net Revenue for veterinary applications and 15% of Net Revenue for human applications.
• The addendum also extends various deadlines in the License Agreement (no specific new dates disclosed in the 8-K summary).
• The addendum document is filed as Exhibit 10.1; a related press release is furnished as Exhibit 99.1.

Why It Matters
This amendment formally enlarges the addressable market for CannEpil® to include animals, creating a potential new revenue stream for Splash Beverage through veterinary sales. The specified royalty rates (10% veterinary, 15% human) are important because they directly affect the company’s gross margins on any CannEpil® sales. Investors should note this is an amendment to an existing license (not an acquisition) and the filing does not provide projected revenue or financial impact — only the contractual terms listed above.